Knight Therapeutics (TSX:GUD) reached agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a letter of intent covering reimbursement of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first buprenorphine implant for the long-term maintenance treatment of opioid addiction.
“Probuphine provides a convenient, confidential and effective option for the treatment of opioid use disorder that can help patients overcome the barriers of daily adherence, including multiple pharmacy visits, giving them a sense of normalcy,” Dr. Lionel Marks de Chabris, assistant professor at the Northern Ontario School of Medicine, and a chronic pain and addiction specialist in Sudbury, Ontario, said in a statement.
“The implant ensures that patients no longer need to worry about missing a dose, not getting a prescription or not getting to their pharmacy on time, which helps normalize their lives and reinforce their recovery,” he added.
Following the agreement with pCPA, Probuphine is listed for reimbursement through the public insurance plans administered by Alberta, Saskatchewan and the Non-Insured Health Benefit. Knight is actively working with other jurisdictions to finalize listings across the country to ensure Canadian patients have public access to this novel treatment option.
“The conclusion of negotiations with pCPA represents a major step in facilitating country-wide access of Canada’s first and only subdermal buprenorphine implant for patients living with opioid use disorder,” said Jonathan Goodman, CEO of Knight.
